Stock Research for SNSS


Featured Broker: Ally Invest

Get the due diligence for another stock.


SNSS Stock Chart & Research Data

The SNSS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SNSS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


SNSS Due diligence Resources & Stock Charts

The SNSS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SNSS Detailed Price Forecast - CNN Money CNN View SNSS Detailed Summary - Google Finance
Yahoo View SNSS Detailed Summary - Yahoo! Finance Zacks View SNSS Stock Research & Analysis -

Stock Analysis

TradeIdeas View SNSS Trends & Analysis - Trade-Ideas Barrons View SNSS Major Holders - Barrons
NASDAQ View SNSS Call Transcripts - NASDAQ Seeking View SNSS Breaking News & Analysis - Seeking Alpha
Spotlight View SNSS Annual Report - OTC Report View SNSS OTC Short Report -
TradeKing View SNSS Fundamentals - TradeKing Charts View SNSS SEC Filings - Bar Chart
WSJ View Historical Prices for SNSS - The WSJ Morningstar View Performance/Total Return for SNSS - Morningstar
MarketWatch View the Analyst Estimates for SNSS - MarketWatch CNBC View the Earnings History for SNSS - CNBC
StockMarketWatch View the SNSS Earnings - StockMarketWatch MacroAxis View SNSS Buy or Sell Recommendations - MacroAxis
Bullish View the SNSS Bullish Patterns - American Bulls Short Pains View SNSS Short Pain Metrics -

Social Media Mentions

StockTwits View SNSS Stock Mentions - StockTwits PennyStocks View SNSS Stock Mentions - PennyStockTweets
Twitter View SNSS Stock Mentions - Twitter Invest Hub View SNSS Investment Forum News - Investor Hub
Yahoo View SNSS Stock Mentions - Yahoo! Message Board Seeking Alpha View SNSS Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for SNSS - Insider Cow View Insider Transactions for SNSS - Insider Cow
CNBC View SNSS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SNSS - OTC Markets
Yahoo View Insider Transactions for SNSS - Yahoo! Finance NASDAQ View Institutional Holdings for SNSS - NASDAQ

Stock Charts

FinViz View SNSS Stock Insight & Charts - StockCharts View SNSS Investment Charts -
BarChart View SNSS Stock Overview & Charts - BarChart Trading View View SNSS User Generated Charts - Trading View

Latest Financial News for SNSS

The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
Posted on Tuesday December 04, 2018

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 3) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...

Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting
Posted on Sunday December 02, 2018

Sunesis Pharmaceuticals, Inc. (SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results will be presented today, December 2, from 6:00-8:00 p.m. PT in a poster session titled “CLL: Therapy, excluding Transplantation: Poster II” at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, California. “To date, vecabrutinib has demonstrated both an encouraging safety profile and evidence of pharmacodynamic activity in CLL and other B cell cancer patients both with and without the BTK C481 mutation,” said Dayton Misfeldt, Sunesis interim Chief Executive Officer. highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
Posted on Thursday November 29, 2018 highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals

5 Top-Ranked Rising P/E Stocks to Lure Investors
Posted on Wednesday November 28, 2018

Inside the top-ranked stocks that have been exhibiting rising P/E ratios.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.